Article
Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
ESMO open - 1 Dec 2022
Wang H-Y, Wu S-G, Lin Y-T, Chen C-Y, Shih J-Y
Abstract excerpt
BACKGROUND: Anaplastic lymphoma kinase-positive (ALK+) and ROS proto-oncogene 1 (ROS1)-positive (ROS1+) lung cancers have been reported to be associated with an elevated risk of thromboembolic events. This study aimed to assess the long-term risk of developing thromboembolism (TE) in ROS1+ lung cancer and to compare it with other oncogenic drivers in the Asian population. MATERIALS AND METHODS: We retrospectively...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.